Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

anti-VEGF/ANG2 nanobody BI 836880

A nanobody directed against angiopoietin-2 (Ang2; ANGPT2)- and vascular endothelial growth factor (VEGF)-derived peptides, with potential antiangiogenic and antineoplastic activities. Anti-VEGF/ANG2 nanobody BI 836880 binds to Ang2 and VEGF and inhibits receptor binding; this prevents Ang2- and VEGF-mediated signaling and inhibits both tumor angiogenesis and tumor cell proliferation. Both VEGF and Ang2 are upregulated in a variety of cancer cell types and each plays a crucial role in angiogenesis. The nanobody is based on functional fragments of single-chain antibodies.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-VEGF/ANG2 BI 836880
bi-specific anti-VEGF/Ang2 nanobody BI 836880
Code name:BI 836880
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search